AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15347469 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 54
Study 11479779 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryonia in a 12c potency
Number of subjects: 70
Study 11479779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9754466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis solution containing 2.5% glucose
Number of subjects: 32
Study 9754466 — intervention group
Group type: COMPARATOR
Intervention: Dialysis solution containing 1.5% glucose
Number of subjects: 32
Study 9754466 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 32
Study 8311013 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT: cisplatin 50 mg/m2 + cyclophosphamide 600 mg/m2 day 1 every 28 days for 6 courses)
Number of subjects: 70
Study 8311013 — intervention group
Group type: COMPARATOR
Intervention: Whole abdominal radiotherapy (WAR: 43.2 Gy/24 fractions to the pelvis and 30.2 Gy to the upper abdomen)
Number of subjects: 70
Study 3392234 — intervention group
Group type: EXPERIMENTAL
Intervention: Doryx (enteric-coated doxycycline hyclate pellets)
Number of subjects: 98
Study 3392234 — intervention group
Group type: COMPARATOR
Intervention: Vibramycin (doxycycline hyclate powder)
Number of subjects: 98
Study 3392234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 30336702 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Number of subjects: 200
Study 30336702 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 200
Study 30336702 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred treatment (either Prolonged exposure or Sertraline)
Number of subjects: 200
Study 28211344 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg white recipe validated in phase 1 (n=89 volunteers)
Number of subjects: 197
Study 28211344 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk recipe validated in phase 2 (n=30 participants)
Number of subjects: 197
Study 28211344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazelnut recipe validated in phase 2 (n=30 participants)
Number of subjects: 197
Study 28211344 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) scores for the 3 recipes
Number of subjects: 197
Study 26701606 — intervention group
Group type: EXPERIMENTAL
Intervention: α-mangostin nanoparticles applied twice daily for 4 weeks
Number of subjects: 10
Study 26701606 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 23294853 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-weekly docetaxel (50 mg/m² on days 1 and 15 of a 4-week cycle)
Number of subjects: 361
Study 23294853 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel (75 mg/m² on day 1 of a 3-week cycle)
Number of subjects: 361
Study 23294853 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly docetaxel
Number of subjects: 361
Study 21511218 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel loading dose (LD)
Number of subjects: 109
Study 21511218 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg clopidogrel loading dose (LD)
Number of subjects: 109
Study 21511218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 300 mg and 900 mg clopidogrel loading doses
Number of subjects: 109
Study 18383517 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiandrogen withdrawal
Number of subjects: 210
Study 16595223 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone 3 mg and ethinyl estradiol 30 microg for 12 cycles
Number of subjects: 50
Study 12904635 — intervention group
Group type: EXPERIMENTAL
Intervention: T50 (50% reduction in training volume)
Number of subjects: 11
Study 12904635 — intervention group
Group type: COMPARATOR
Intervention: T30 (30% reduction in training volume)
Number of subjects: 11
Study 12904635 — intervention group
Group type: COMPARATOR
Intervention: T80 (80% reduction in training volume)
Number of subjects: 11
Study 10834865 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent SAARD with a short lag time (methotrexate, if necessary replaced by sulfasalazine)
Number of subjects: 0
Study 10834865 — intervention group
Group type: EXPERIMENTAL
Intervention: Potent SAARD with a long lag time (intramuscular gold, if necessary replaced by D-penicillamine)
Number of subjects: 0
Study 10834865 — intervention group
Group type: COMPARATOR
Intervention: Mild SAARD with a long lag time (hydroxychloroquine, if necessary replaced by auranofin)
Number of subjects: 0
Study 9113250 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-proof vodka (1.5 ml/kg) in orange juice
Number of subjects: 9
Study 9113250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8458059 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg/hr cimetidine
Number of subjects: 21
Study 8458059 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/hr cimetidine
Number of subjects: 21
Study 8458059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3462467 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and Prednisone (VP)
Number of subjects: 137
Study 3462467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Prednisone, and Anthracycline (VPA)
Number of subjects: 137
Study 3462467 — intervention group
Group type: COMPARATOR
Intervention: Vincristine and Prednisone (VP) for boys
Number of subjects: 137
Study 3462467 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine, Prednisone, and Anthracycline (VPA) for boys
Number of subjects: 137
Study 30587220 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion with sexual partner
Number of subjects: 648
Study 30587220 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion with peers
Number of subjects: 648
Study 30587220 — intervention group
Group type: EXPERIMENTAL
Intervention: Not co-residing with both parents
Number of subjects: 648
Study 30587220 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-perception of HIV risk
Number of subjects: 648
Study 26809009 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee osteoarthritis subjects
Number of subjects: 46
Study 26809009 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study 25604307 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-CHE
Number of subjects: 40
Study 25604307 — intervention group
Group type: COMPARATOR
Intervention: CLC
Number of subjects: 40
Study 23083841 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP
Number of subjects: 1049
Study 23083841 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CRP (standardised to 1SD) during follow-up
Number of subjects: 1049
Study 19486488 — intervention group
Group type: COMPARATOR
Intervention: Concentric reinforcement (CG)
Number of subjects: 18
Study 19486488 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric reinforcement (EG)
Number of subjects: 18
Study 18973097 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine plus montelukast
Number of subjects: 40
Study 18973097 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast plus levocetirizine
Number of subjects: 40
Study 18973097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16049637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (mean dose 8.6 +/- 1.3 mg) for 12 months
Number of subjects: 11
Study 16049637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine (mean dose 10.5-12 mg) for 12 months
Number of subjects: 11
Study 16049637 — intervention group
Group type: COMPARATOR
Intervention: Untreated group of 10 AD patients
Number of subjects: 11
Study 14597933 — intervention group
Group type: EXPERIMENTAL
Intervention: GUSTO trial
Number of subjects: 3
Study 14597933 — intervention group
Group type: COMPARATOR
Intervention: NRMI
Number of subjects: 3
Study 14597933 — intervention group
Group type: COMPARATOR
Intervention: CCP
Number of subjects: 3
Study 11205684 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-classical trial designs
Number of subjects: 0
Study 11205684 — intervention group
Group type: COMPARATOR
Intervention: Classical clinical trial designs
Number of subjects: 0
Study 8726592 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 8726592 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (maximum dosages)
Number of subjects: 0
Study 1457622 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg denbufylline BID
Number of subjects: 96
Study 1457622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 6326784 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prenalterol (5 mg)
Number of subjects: 7
Study 6326784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained oral prenalterol (100 mg twice a day)
Number of subjects: 7
Study 6326784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during oral crossover study)
Number of subjects: 7
Study 30983953 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL-BWSTT
Number of subjects: 18
Study 30983953 — intervention group
Group type: COMPARATOR
Intervention: CPT
Number of subjects: 18
Study 30983953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies (HAL-BWSTT and CPT)
Number of subjects: 18
Study 27739626 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychosocial intervention
Number of subjects: 314
Study 27739626 — intervention group
Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 314
Study 26266401 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (IPL + NIR + fractional Er:YAG laser)
Number of subjects: 113
Study 26266401 — intervention group
Group type: COMPARATOR
Intervention: IPL monotherapy
Number of subjects: 113
Study 25293442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle weight loss group (LWL)
Number of subjects: 30
Study 25293442 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 30
Study 21703942 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium calcium citrate (PCC)
Number of subjects: 24
Study 19231488 — intervention group
Group type: EXPERIMENTAL
Intervention: Precut procedure performed immediately after randomization (Group A)
Number of subjects: 146
Study 19231488 — intervention group
Group type: COMPARATOR
Intervention: Standard cannulation attempts followed by needle-knife precut if necessary (Group B)
Number of subjects: 146
Study 17468667 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Switch (IS) arm
Number of subjects: 147
Study 17468667 — intervention group
Group type: COMPARATOR
Intervention: Structured Treatment Interruption (STI) arm
Number of subjects: 147
Study 17468667 — intervention group
Group type: COMPARATOR
Intervention: STI arm
Number of subjects: 147
Study 17468667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 147
Study 15458587 — intervention group
Group type: EXPERIMENTAL
Intervention: Left and bilateral infarctions
Number of subjects: 170
Study 15458587 — intervention group
Group type: EXPERIMENTAL
Intervention: Left infarctions
Number of subjects: 170
Study 15458587 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of SAH
Number of subjects: 170
Study 15458587 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin scale
Number of subjects: 170
Study 15458587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tests
Number of subjects: 170
Study 15458587 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire ratings of mental impairments
Number of subjects: 170
Study 15978307 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg
Number of subjects: 120
Study 15978307 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 75 mg
Number of subjects: 120
Study 15978307 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 25 mg
Number of subjects: 120
Study 15978307 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle)
Number of subjects: 120
Study 15978307 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg vs 25 mg
Number of subjects: 120
Study 15978307 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 75 mg vs 25 mg
Number of subjects: 120
Study 10481502 — intervention group
Group type: EXPERIMENTAL
Intervention: Musicians (DPOAE measurements)
Number of subjects: 82
Study 10481502 — intervention group
Group type: EXPERIMENTAL
Intervention: Absolute pitch possessors (APP)
Number of subjects: 82
Study 10481502 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative pitch possessors (RPP)
Number of subjects: 82
Study 10481502 — intervention group
Group type: COMPARATOR
Intervention: Non-musicians (Control group)
Number of subjects: 82
Study 8752873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transbasal & transfacial approach (Type A)
Number of subjects: 19
Study 8752873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transbasal & transfacial approach (Type B)
Number of subjects: 19
Study 8752873 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined transbasal & transfacial approach (Type C)
Number of subjects: 19
Study 1842010 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipi tea
Number of subjects: 14
Study 1842010 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea (Imperata exaltata - sape)
Number of subjects: 14
Study 6277020 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar-containing biscuit; specific dosage and duration not mentioned.
Number of subjects: 0
Study 30633181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvis reposition exercise (15-minute trial)
Number of subjects: 30
Study 30633181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 30282142 — intervention group
Group type: EXPERIMENTAL
Intervention: Water caloric test
Number of subjects: 60
Study 30282142 — intervention group
Group type: COMPARATOR
Intervention: Air caloric test
Number of subjects: 60
Study 27784733 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2993
Study 27784733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 2993
Study 27784733 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 2993
Study 24571932 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini booster (telephone MI sessions)
Number of subjects: 282
Study 24571932 — intervention group
Group type: EXPERIMENTAL
Intervention: Full booster (face to face MI sessions)
Number of subjects: 282
Study 24571932 — intervention group
Group type: COMPARATOR
Intervention: Control (no further intervention)
Number of subjects: 282
Study 22910336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous stitches
Number of subjects: 124
Study 22910336 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 124
Study 22910336 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of the fat layer
Number of subjects: 124
Study 22910336 — intervention group
Group type: COMPARATOR
Intervention: No closure of the fat layer
Number of subjects: 124
Study 20701514 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg with FSH
Number of subjects: 280
Study 20701514 — intervention group
Group type: COMPARATOR
Intervention: Letrozole 5 mg daily with FSH
Number of subjects: 280
Study 20701514 — intervention group
Group type: COMPARATOR
Intervention: Letrozole group
Number of subjects: 280
Study 20701514 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate group
Number of subjects: 280
Study 20701514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 280
Study 17414743 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60‐120 mg/day
Number of subjects: 487
Study 17414743 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75‐225 mg/day
Number of subjects: 487
Study 17414743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 16288616 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin ointment
Number of subjects: 186
Study 16288616 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 186
Study 14606379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane terminated 30 minutes before awakening (Group A)
Number of subjects: 80
Study 14606379 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane terminated 10 minutes before awakening (Group B)
Number of subjects: 80
Study 10188750 — intervention group
Group type: EXPERIMENTAL
Intervention: Push-up (PU)
Number of subjects: 10
Study 10188750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench press-load (BP-L)
Number of subjects: 10
Study 10188750 — intervention group
Group type: COMPARATOR
Intervention: Bench press-no load (BP-NL)
Number of subjects: 10
Study 7797058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0
Study 7797058 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin desensitization
Number of subjects: 0
Study 7797058 — intervention group
Group type: EXPERIMENTAL
Intervention: New anti-inflammatory agents (methotrexate, hydroxychloroquine, auronifin, sulfonylureas)
Number of subjects: 0
Study 30782354 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported medication nonadherence measure
Number of subjects: 236
Study 28976437 — intervention group
Group type: EXPERIMENTAL
Intervention: IKACTA tool
Number of subjects: 16
Study 28976437 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional learning material)
Number of subjects: 16
Study 25799447 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 Clearfil SE Bond/Filtek Z350
Number of subjects: 27
Study 25799447 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 Adper Easy One/Filtek Z350
Number of subjects: 27
Study 25799447 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 P90 Adhesive System/Filtek P90
Number of subjects: 27
Study 23639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (120 Hz/low-intensity) applied homotopically, over the left common peroneal nerve
Number of subjects: 20
Study 23639375 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (2 Hz/low-intensity) positioned heterotopically, over the left thigh
Number of subjects: 20
Study 23639375 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS (replication of condition T1)
Number of subjects: 20
Study 23639375 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS (120 Hz/low-intensity)
Number of subjects: 20
Study 21284838 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief tailored psychosocial intervention delivered by trained health professionals, up to 4 sessions of 30 minutes each, face-to-face or by telephone.
Number of subjects: 600
Study 21284838 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified in detail).
Number of subjects: 600
Study 18035191 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 302
Study 18035191 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 302
Study 18035191 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% (open-label phase)
Number of subjects: 302
Study 18035191 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% switched to Travoprost 0.004% (open-label phase)
Number of subjects: 302
Study 18035191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular adverse events (AEs) with Travoprost
Number of subjects: 302
Study 18035191 — intervention group
Group type: COMPARATOR
Intervention: Ocular adverse events (AEs) with Latanoprost
Number of subjects: 302
Study 18035191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular adverse events (AEs) with Open-label Travoprost
Number of subjects: 302
Study 16030053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (initiated at 30 mg, escalated to a maximum of 180 mg once daily)
Number of subjects: 59
Study 16030053 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet (30 mg to 180 mg once daily)
Number of subjects: 59
Study 11799484 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC, prednisone, and MMF therapy (group T)
Number of subjects: 106
Study 11799484 — intervention group
Group type: COMPARATOR
Intervention: TAC and prednisone therapy (group D)
Number of subjects: 106
Study 10618943 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand tactile assessment using TOF
Number of subjects: 0
Study 10618943 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand tactile assessment using DBS3,3
Number of subjects: 0
Study 10618943 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand tactile assessment using DBS3,2
Number of subjects: 0
Study 10618943 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand tactile assessment of ulnar nerve stimulation
Number of subjects: 0
Study 8955458 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic ventricular septal defect (VSD) group
Number of subjects: 26
Study 8955458 — intervention group
Group type: COMPARATOR
Intervention: Healthy infants (control group)
Number of subjects: 26
Study 1658281 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber-supplemented formula (Isomil plus soy polysaccharide)
Number of subjects: 27
Study 1658281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Isomil formula)
Number of subjects: 27
Study 6181324 — intervention group
Group type: EXPERIMENTAL
Intervention: BHT-933 5 mg
Number of subjects: 9
Study 6181324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31755968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept 1.25 mg
Number of subjects: 123
Study 31755968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (IVB)
Number of subjects: 123
Study 31755968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ziv-aflibercept 2.5 mg
Number of subjects: 123
Study 30172362 — intervention group
Group type: EXPERIMENTAL
Intervention: JVD only
Number of subjects: 7135
Study 30172362 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral edema only
Number of subjects: 7135
Study 30172362 — intervention group
Group type: EXPERIMENTAL
Intervention: JVD and peripheral edema
Number of subjects: 7135
Study 30172362 — intervention group
Group type: COMPARATOR
Intervention: No JVD or peripheral edema
Number of subjects: 7135
Study 30172362 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1-4)
Number of subjects: 7135